However, both overestimation and underestimation of residual disease extent could be observed.
Importantly, MR provides the best estimate of disease extent and contralateral breast involvement.
Patient symptoms were recorded in 80 trials (86%) and disease extent in 62 trials (67%).
Magnetic resonance (MR) imaging may be helpful in confirming a diagnosis while providing anatomical detail and delineating disease extent.
The combined 18F NaFDG8F FDG PET/MRI is superior to 99mTc-MDP scintigraphy for evaluation of skeletal disease extent.
Although the initial diagnosis is based on ophthalmoscopy and US, cross-sectional imaging is mandatory to assess disease extent and prognosis.
In general, the disease extent appears larger on MRI than on CT; therefore, a combined MRI and CT assessment is most often required pre-operatively.
In this systematic review, we aimed to address the role of breast MRI in assessing both residual disease extent and pCR after NAC in breast cancer patients.
Molecular imaging has been found to outperform conventional imaging for assessment of disease extent in cases of BCR [11, 12, 14, 15].
Contemporary breast imaging techniques are essential in documenting disease extent, providing guidance during percutaneous core needle biopsy and in helping to exclude malignancy.
Resulting segmentation of uptake regions (PET S) and segmented regions with PET intensity values (PET T) are used for quantification and monitoring of the disease extent.
